Inoviq Ltd (ASX: IIQ) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Inoviq Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $53.83 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 92.02 million
Earnings per share -0.071
Dividend per share N/A
Year To Date Return -10.53%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Inoviq Ltd (ASX: IIQ)
    Latest News

    Young doctor raising arms in air with hands in fists celebrating a new development
    Healthcare Shares

    Why the BARD1 (ASX:BD1) share price is on the rise today

    The BARD1 Life Sciences Ltd (ASX: BD1) share price is climbing today following a postiive update from the company. We…

    Read more »

    Starpharma share price A doctor or medical expert in COVID-19 protection flexes his muscle, indicating growth or strong share price movement in ASX medical, biotech and health companies
    Healthcare Shares

    Why is the BARD1 (ASX:BD1) share price jumping today?

    The BARD1 Life Sciences Ltd (ASX: BD1) share price is rising significantly today, adding to strong yearly gains, after the company released…

    Read more »

    Starpharma share price A doctor or medical expert in COVID-19 protection flexes his muscle, indicating growth or strong share price movement in ASX medical, biotech and health companies
    Share Market News

    Why the BARD1 (ASX:BD1) share price shot up 10% today

    The BARD1 (ASX: BD1) share price is up today after the company signed an agreement that will help in type…

    Read more »

    A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
    Share Market News

    The BARD1 (ASX:BD1) share price eyes record highs after positive research results

    The BARD1 Life Sciences Ltd (ASX: BD1) share price is eyeing a new record high today after positive results from…

    Read more »

    Young doctor raising arms in air with hands in fists celebrating a new development
    Share Market News

    Why the BARD1 (ASX:BD1) share price is climbing 6% today

    The BARD1 Life Sciences Ltd (ASX: BD1) share price is climbing today following a favourable outcome for the company's hTERT…

    Read more »

    A man stands with arms crossed in front of a giant shadow of a body builder representing ASX small-cap stocks.
    Share Market News

    These small cap ASX shares surged more than 100% in February

    From a new BNPL agreement to cancer detection, these 3 small cap ASX shares made game changing announcements in February.

    Read more »

    falling healthcare asx share price Mesoblast capital raising
    ⏸️ ASX Shares

    BARD1 (ASX:BD1) share price plummets 15% on legal proceedings

    The BARD1 (ASX: BD1) share price took a major hit today after the company announced legal proceedings are being brought…

    Read more »

    Young doctor raising arms in air with hands in fists celebrating a new development
    Share Market News

    Why the BARD1 Life Sciences (ASX:BD1) share price is rocketing another 54% today

    The BARD1 Life Sciences (ASX:BD1) share price is rocketing again today, up 54% so far. We look at the company's…

    Read more »

    woman in lab coat conducting testing representing biotech
    Share Market News

    Why is the BARD1 Life Sciences (ASX:BD1) share price rocketing 78%?

    The BARD1 Life Sciences share price is up an eye-popping 78% in early afternoon trading. We look at what's driving…

    Read more »

    IIQ ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Inoviq Ltd

    Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers.

    IIQ Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    27 Mar 2024 $0.59 $-0.01 -1.68% 8,455 $0.59 $0.59 $0.59
    26 Mar 2024 $0.60 $0.01 1.69% 80,156 $0.59 $0.60 $0.57
    25 Mar 2024 $0.59 $0.02 3.51% 31,083 $0.58 $0.60 $0.58
    22 Mar 2024 $0.57 $-0.01 -1.72% 49,222 $0.59 $0.59 $0.57
    21 Mar 2024 $0.58 $-0.01 -1.71% 56,766 $0.59 $0.60 $0.58
    20 Mar 2024 $0.59 $-0.01 -1.69% 53,371 $0.60 $0.61 $0.59
    19 Mar 2024 $0.59 $0.03 5.31% 110,264 $0.58 $0.60 $0.57
    18 Mar 2024 $0.57 $-0.01 -1.75% 7,086 $0.58 $0.58 $0.57
    15 Mar 2024 $0.57 $0.00 0.00% 112,524 $0.60 $0.60 $0.57
    14 Mar 2024 $0.57 $-0.04 -6.56% 239,027 $0.61 $0.61 $0.56
    13 Mar 2024 $0.61 $0.01 1.67% 44,421 $0.60 $0.61 $0.60
    12 Mar 2024 $0.60 $-0.01 -1.65% 62,408 $0.61 $0.62 $0.59
    11 Mar 2024 $0.61 $-0.01 -1.63% 128,711 $0.62 $0.62 $0.60
    08 Mar 2024 $0.62 $-0.02 -3.17% 108,249 $0.62 $0.62 $0.62
    07 Mar 2024 $0.63 $-0.01 -1.56% 39,418 $0.64 $0.64 $0.62
    06 Mar 2024 $0.64 $-0.04 -5.93% 68,199 $0.67 $0.68 $0.64
    05 Mar 2024 $0.68 $0.02 3.05% 12,051 $0.66 $0.68 $0.66
    04 Mar 2024 $0.66 $0.02 3.15% 278,405 $0.64 $0.70 $0.64
    01 Mar 2024 $0.64 $-0.05 -7.35% 143,655 $0.69 $0.69 $0.63
    29 Feb 2024 $0.68 $-0.01 -1.44% 32,333 $0.70 $0.72 $0.68
    28 Feb 2024 $0.70 $0.03 4.51% 9,819 $0.66 $0.70 $0.65
    27 Feb 2024 $0.67 $-0.04 -5.67% 79,657 $0.68 $0.70 $0.66

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr David Williams Non-Executive ChairmanNon-Executive Director Nov 2023
    --
    Mr Philip (Phil) John Powell Non-Executive Director Jun 2019
    Mr Powell has experience in investment banking, specialising in capital raisings, initial public offerings (IPOs), mergers and acquisitions and other corporate finance assignments across a diverse range of sectors including pharma, utilities, IT, financial services, food, and agriculture. He spent 10 years in senior financial roles at OAMPS Ltd, a former ASX-listed financial services group, and 10 years in audit with Arthur Andersen & Co in Melbourne, Sydney, and Los Angeles.
    Mr Geoffrey A. Cumming Non-Executive ChairmanNon-Executive Director Jul 2020
    Dr Cumming has held senior roles in the global healthcare and biotechnology sector for more than 20 years. As Managing Director, Roche Diagnostic Systems (Oceania), Dr Cumming transformed the loss-making entity the Swiss parent was intending to divest, into the growing and profitable affiliate in the Roche group. In his role as Managing Director/CEO of Biosceptre International Ltd, Dr Cumming was in designing and securing key funding arrangements through a range of capital raising initiatives, including government grants, partnering and co-development deals. He is Member of Risk Committee.
    Mr Robert (Max) Maxwell Johnston Non-Executive Director Jun 2019
    Mr Johnston held the position of President and Chief Executive Officer of Johnson & Johnson Pacific, a division of the medical, pharmaceutical and consumer healthcare company for 11 years. Prior to joining Johnson & Johnson, Mr Johnston's career also included senior roles with Diageo and Unilever in Australia, Africa, and Europe. Mr Johnston has also held several industry roles as a past President of ACCORD Australasia Limited, a former Vice Chairman of the Australian Food and Grocery Council and a former member of the board of the Australian Self Medication Industry (ASMI). Mr Johnston has had extensive overseas experience during his career in leading businesses in both Western and Central-Eastern Europe and Africa as well as the Asia-Pacific region. He is Member of Risk Committee.
    Dr Leearne Hinch Chief Executive Officer Nov 2016
    -
    Mr Mark Edwards Chief Financial OfficerCompany Secretary Nov 2022
    -
    Leearne Hinch Chief Executive Officer
    -
    Mark Edwards Chief Financial OfficerCompany Secretary
    -
    Dr Gregory Rice Chief Scientific Officer
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    The Trust Company Australia Limited <Mof A/C> 6,457,000 7.02%
    Dr Irmgard Irminger Finger 3,445,829 3.74%
    Lawn Views Pty Ltd <Angela Williams Family A/C> 2,676,924 2.91%
    The Trust Company (Australia) Limited <Mbf A/C> 2,248,333 2.44%
    Moggs Creek Pty Ltd <Moggs Creek Super A/C> 2,209,747 2.40%
    Lesamourai Pty Ltd 2,000,000 2.17%
    BNP Paribas Nominees Pty Ltd <IB AU NOMS Retailclient DRP> 1,956,453 2.13%
    J P Morgan Nominees Australia Pty Limited 1,508,353 1.64%
    Mr Peter William Rogers & Ms Alida Johanna Clark <R&C Super Fund A/C> 1,217,245 1.32%
    Traoj Pty Ltd <Traoj A/C> 1,102,933 1.20%
    Supergun Pty Ltd <Bricklanding Super Fund A/C> 1,030,000 1.12%
    Mr Nathan Ryan Wagner 1,010,562 1.10%
    Mr Adam Garrigan 1,000,000 1.09%
    David Neate 902,257 0.98%
    Trovex Pty Ltd 820,000 0.89%
    Dr Russell Kay Hancock 750,000 0.82%
    Citicorp Nominees Pty Limited 717,669 0.78%
    B & M Laws Super Fund Pty Ltd <B & M Laws Super Fund A/C> 600,000 0.65%
    Ll&P Pty Ltd <The Andrew Solomons S/F A/C> 584,095 0.63%
    P R Perry Nominees Pty Ltd <Donesk Family A/C> 561,000 0.61%

    Profile

    since

    Note